Development of a new integrated model to speed up the identification and development of drug candidates for treating nervous system diseases. Reduction in the failure rate of molecules that advance during the pre-clinical and clinical development process, to enable decisions to be made early in the process and help optimise resources and achieve better, more effective medicines for this group of diseases.